A Meta-Analysis Of Effrct And Safety Of Celecoxib In Combination With Chemoradiotherapy In Treatment Of Advanced Non Small Cell Lung Cancer

Objective:To evaluate therapeutic efficacy and safety of celecoxib combined with chemoradiotherapy vs. chemoradiotherapy alone in the treatment of advanced non-small cell lung cancer (NSCLC), and to provide evidence-based reference for clinical treatment.Methods:Retrieved from PubMed, EMbase, Cochrane Library, CNKI, VIP and WanFang databases by computer, randomized controlled trials (RCTs) about celecoxib in combination with Chemoradiotherapy in treatment of advanced NSCLC were included. According to the inclusive and exclusive criteria, literatures and data were independently screened and extracted by two researchers, and the quality of the studies were assessed, Meta-analysis was conducted by RevMan 5.2 software.Results:A total of 8 RCT were included, involving 1 319 patients. Meta-analysis showed that experiment group could significantly improve response rate [OR=1.35,95%CI (1.06,1.73), P=0.02], but increased the incidence of ADR [OR=2.52,95% CI (1.81,3.50), P<0.000]; there was statistical difference between control group and experiment group. There were no significant differences in median survival time [MD =-0.35,95%CI (-1.58,0.51), P=0.32] and 1-year survival rate [OR = 1.21,95%CI (0.95,1.53), P=0.12] between 2 groupsConclusion:celecoxib could improve advanced NSCLC overall response rate, but increase the risk of adverse events, while have no obvious effect on median survival time,1 year survival rate, and combination group treatment depends on individual conditions.